Floatz logo

[111in]-fpi-2058

Neuroendocrine Differentiated (NED) Prostate Cancer

3B Pharmaceuticals GmbHradiopharmaceuticalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Neuroendocrine Differentiated (NED) Prostate Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Phanes Therapeutics
Phase 2BB
Oxodotreotide
Novartis Pharmaceuticals
Phase 2B
Tarlatamab
Inkeun Park
Phase 2B
Alisertib
Weill Medical College of Cornell University
Phase 2B
Nivolumab
Andrew J. Armstrong, MD
Phase 2CCC

View all 35 →

Same molecule, other indications

[111in]-fpi-2058 is also rated in:

NTSR1 Expressing Solid TumoursDormant
CC
Indicative ·
43 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
Ewing sarcomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →